SCHEMBL3207986

SCHEMBL3207986

CC(c1ccc(Br)cc1)N(CCCC(=N[S+]([O-])C(C)(C)C)c1ccccc1)C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 3/20 0.33
PMP22 Q01453 1/20 0.32
ALOX5 P09917 1/20 0.32
KMT2A Q03164 3/20 0.31
MEN1 O00255 2/20 0.31
TMEM97 Q5BJF2 1/20 0.30
SIGMAR1 Q99720 1/20 0.30
CHRM2 P08172 2/20 0.30
CHRM1 P11229 2/20 0.30
DRD1 P21728 2/20 0.30
SLC6A2 P23975 2/20 0.30
SLC6A4 P31645 2/20 0.30
HRH1 P35367 2/20 0.30
SLC6A3 Q01959 2/20 0.30
KCNH2 Q12809 2/20 0.30
HRH3 Q9Y5N1 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3207967 1.00 ALDH1A1 (0.35) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL3207972 1.00 ALDH1A1 (0.35) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL3207981 1.00 ALDH1A1 (0.35) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL3208531 1.00 ALDH1A1 (0.35) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL3207998 1.00 ALDH1A1 (0.35) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL9962946 0.90 ESRRB (0.35) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL9962949 0.90 ESRRB (0.35) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL3765652 0.85 ALDH1A1 (0.38) ALDH1A1KDM4EMAPTALOX5DRD1
SCHEMBL3765658 0.85 ALDH1A1 (0.38) ALDH1A1KDM4EMAPTALOX5DRD1
SCHEMBL3655844 0.85 ALDH1A1 (0.38) ALDH1A1KDM4EMAPTALOX5DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202857-B2 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase 1 VITAE PHARMACEUTICALS, INC. (US) 2012-06-19 US disclosed
EP-2252598-A2 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 Vitae Pharmaceuticals, Inc. (US) 2010-11-24 EP disclosed
US-20100041637-A1 1,3-Oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase 1 VITAE PHARMACEUTICALS, INC. (US) 2010-02-18 US disclosed
WO-2009102428-A2 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 VITAE PHARMACEUTICALS, INC. (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041637-A1 1,3-Oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase 1 HSD11B1, HSD17B1, HSD3B1 ALDH1A1 82/4885KDM4E 4488/4885MAPT 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.